Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Primary Immunodeficiency Diseases

• A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants
• A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)
• Allogeneic Hematopoietic Stem Cell Transplant for People With Primary Immunodeficiency Diseases
• Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide
• Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases
• CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL
• Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
• Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome
• Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
• EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
• Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
• Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
• Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
• IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia
• CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL
• Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
• Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases
• ASIS for GAMMAGARD in Primary Immunodeficiency
• Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant
• Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml
• Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
• Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
• Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency
• Evaluation of Efficacy and Tolerability of Hizentra®
• Phase 2/3 Study of IGSC, 20% in PIDD
• Study of Vitamin D3 Substitution to Patients With Primary Immunodeficiency
• Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases
• Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency
• Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders
• Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
• Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency
• Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)
• Subcutaneous Ig NextGen 16% in PID Patients
• Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Nonca
• Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
• Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
• Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)
• Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)